198084-12-7

Usage

Uses

Used in Organic Synthesis:
4-(PYRIMIDIN-5-YL)BENZALDEHYDE is used as a reactant and reagent for the synthesis of various organic compounds. Its presence in reactions can lead to the formation of different products with potential applications in various fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(PYRIMIDIN-5-YL)BENZALDEHYDE is used as a key intermediate in the synthesis of drugs with potential therapeutic properties. Its unique structure allows for the development of new molecules with specific biological activities.
Used in Chemical Research:
4-(PYRIMIDIN-5-YL)BENZALDEHYDE is also utilized in chemical research for studying reaction mechanisms and exploring new synthetic pathways. Its reactivity with different reagents can provide insights into the behavior of similar compounds and contribute to the advancement of organic chemistry.
Used in Material Science:
In material science, 4-(PYRIMIDIN-5-YL)BENZALDEHYDE can be employed in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to the creation of substances with unique characteristics, such as improved stability or enhanced reactivity.
Overall, 4-(PYRIMIDIN-5-YL)BENZALDEHYDE is a versatile compound with a wide range of applications across different industries, including pharmaceuticals, chemical research, and material science. Its utility in organic synthesis and its potential for developing new drugs and materials make it a valuable component in the field of chemistry.

InChI:InChI=1/C11H8N2O/c14-7-9-1-3-10(4-2-9)11-5-12-8-13-6-11/h1-8H

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 87199-17-5 4-formylphenylboronic acid, 
• 2036-41-1 5-methylpyrimidine 
• 503176-52-1 5-chloropyrimidine hydrochloride 
• 68-12-2 N,N-dimethyl-formamide 
• 87199-16-4 3-Formylphenylboronic acid 

Downstream Products

• 216959-91-0 4-[Pyrimidin-5-yl]-Benzoic Acid 
• 198084-13-8 4-pyrimidin-5-yl-phenyl-methanol 
• 1115090-38-4 4-(3',5'-C₄H₃N₂)C₆H₄CHNCH₂CH₂NMe₂ 
• 1259390-52-7 4,4-bis(hydroxymethyl)-2-(4-[pyrimidine-5-yl]phenyl)oxazolidine 
• 1186485-07-3 4-(pyrimidin-5-yl)benzyl methanesulfonate 
• 1584164-92-0 4'-[4-(pyrimidin-5-yl)phenyl]-4,4':6',2-terpyridine 

Relevant academic research and scientific papers

Synthesis of zwitterionic palladium complexes and their application as catalysts in cross-coupling reactions of aryl, heteroaryl and benzyl bromides with organoboron reagents in neat water

N-(3-Chloro-2-quinoxalinyl)-N′-arylimidazolium salts (aryl = 2,6-diisopropylphenyl [HL1Cl]Cl, aryl = mesityl [HL2Cl]Cl) have been synthesized by treating 2,3-dichloroquinoxaline with the corresponding N′-arylimidazole in neat water. Facile reactions of these imidazolium salts with Pd(PPh3)4 and Pd2(dba)3/PPh3 (dba = dibenzyledene acetone) at 50 °C have afforded zwitterionic palladium(ii) complexes [Pd(HL1)(PPh3)Cl2] (I) and [Pd(HL2)(PPh3)Cl2] (II) in excellent yields. I and II have been tested for their ability to catalyze Suzuki-Miyaura cross coupling (SMC) reactions in neat water/K2CO3 and are found to be highly active for carrying out these reactions between aryl bromides and organoboron reagents. Furthermore, the scope of the catalyst I was also examined by employing (hetero)aryl bromides, hydrophilic aryl bromides, benzyl bromides and various organoboron reagents. More than 80 aryl/benzyl bromide-arylboronic acid combinations were screened in neat water/K2CO3 and it was found that I was a versatile catalyst, which produced biaryls/diarylmethanes in excellent yields. A TON of 82 000 was achieved by using I. Studies on the mechanism have also been carried out to investigate the involvement of carbene complexes in the catalytic path. Poison tests and a two-phase test were also conducted and the results are reported.

Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: Potent inhibitors of R5 HIV-1 replication

The redesign of the previously reported thiophene-3-yl-methyl urea series, as a result of potential cardiotoxicity, was successfully accomplished, resulting in the identification of a novel potent series of CCR5 antagonists containing the imidazolidinylpiperidinyl scaffold. The main redesign criteria were to reduce the number of rotatable bonds and to maintain an acceptable lipophilicity to mitigate hERG inhibition. The structure-activity relationship (SAR) that was developed was used to identify compounds with the best pharmacological profile to inhibit HIV-1. As a result, five advanced compounds, 6d, 6e, 6i, 6h, and 6k, were further evaluated for receptor selectivity, antiviral activity against CCR5 using (R5) HIV-1 clinical isolates, and in vitro and in vivo safety. On the basis of these results, 6d and 6h were selected for further development.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Mild iodine-magnesium exchange of iodoaromatics bearing a pyrimidine ring with isopropylmagnesium chloride

Iodoaromatics bearing a reactive pyrimidine ring underwent a clean iodine-magnesium exchange with isopropylmagnesium chloride in the presence of bis[2-(N,N-dimethylamino)ethyl] ether to provide the corresponding Grignard reagents. The presence of bis[2-(N

Methods of treatment using an EP2 selective receptor agonist

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

PIPERIDINES USEFUL FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The invention relates to compounds which are substituted chiral or achiral derivatives of 3- or 4- aminopiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of β-secretases.

SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE

The invention relates to novel compounds, which are substituted chiral or achiral derivatives of 3- or 4- aminomethylpiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula (I) and especially their use as inhibitors of beta-secretases for the treatment of Alzheimer’s disease.

6-O-carbamate-11,12-lacto-ketolide antimicrobials

6-O-Carbamate-11,12-lacto-ketolide antimicrobials of the formula: wherein R1, R2, R3 R7, and R8 are as described herein and in which the substituents have the meaning indicated in the description. These compounds are useful as antibacterial agents.